147 related articles for article (PubMed ID: 2499263)
41. Extremely high levels of CA19-9 and CA125 antigen in benign mucinous ovarian cystadenoma.
Ye C; Ito K; Komatsu Y; Takagi H
Gynecol Oncol; 1994 Feb; 52(2):267-71. PubMed ID: 7508878
[TBL] [Abstract][Full Text] [Related]
42. [Clinical evaluation of serum CA-50 and CA 19-9 in gynecological tumors].
Suzuki M; Ohwada M; Tamada T; Sakurabayashi I; Kawai T
Rinsho Byori; 1989 Jul; 37(7):784-8. PubMed ID: 2558243
[TBL] [Abstract][Full Text] [Related]
43. [CA 125 in the diagnosis and evaluation of the efficacy of the treatment of cancer of the ovaries].
Sagan DL; Chebotareva ED; Evtushenko GV
Med Radiol (Mosk); 1989 Jun; 34(6):39-42. PubMed ID: 2739519
[TBL] [Abstract][Full Text] [Related]
44. Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer.
Scambia G; Panici PB; Baiocchi G; Perrone L; Iacobelli S; Mancuso S
Anticancer Res; 1988; 8(4):761-4. PubMed ID: 3178164
[TBL] [Abstract][Full Text] [Related]
45. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance.
Garzetti GG; Ciavattini A; Goteri G; De Nictolis M; Stramazzotti D; Lucarini G; Biagini G
Gynecol Oncol; 1995 Feb; 56(2):169-74. PubMed ID: 7896180
[TBL] [Abstract][Full Text] [Related]
46. [Blood serum galactosyltransferase in oncologic diseases].
Mikhaĭlov AD; Zhordaniia KI; Ivanov PK
Med Radiol (Mosk); 1989 Mar; 34(3):31-4. PubMed ID: 2494414
[TBL] [Abstract][Full Text] [Related]
47. [The values of urine cysteine protein activity in the diagnosis of ovarian cancer].
Xi MR; Peng ZL; Cao ZY
Zhonghua Fu Chan Ke Za Zhi; 1994 Feb; 29(2):85-7, 123. PubMed ID: 8033632
[TBL] [Abstract][Full Text] [Related]
48. [Study of the mechanism of tumor marker CA125 in serum].
Kiyozuka Y; Noda T; Adachi S; Adachi S; Akada S; Ichijo M
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1951-8. PubMed ID: 2592818
[TBL] [Abstract][Full Text] [Related]
49. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay.
Chien CH; Huang CC; Lin YH; Shen J; Chow SN
Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253
[TBL] [Abstract][Full Text] [Related]
50. Significance of some tumor markers in differential diagnosis of ovarian tumor.
Zakrzewska I; Borawska R; Poznański J; Maćkowiak B
Rocz Akad Med Bialymst; 1999; 44():235-43. PubMed ID: 10697438
[TBL] [Abstract][Full Text] [Related]
51. Clinical value of CA125, CA19-9, CEA, CA72-4, and TPA in borderline ovarian tumor.
Tamakoshi K; Kikkawa F; Shibata K; Tomoda K; Obata NH; Wakahara F; Tokuhashi Y; Ishikawa H; Kawai M; Tomoda Y
Gynecol Oncol; 1996 Jul; 62(1):67-72. PubMed ID: 8690294
[TBL] [Abstract][Full Text] [Related]
52. A new tumour marker assay for ovarian cancer on the OPUS immunoassay system.
Molz P; Teuter C; Schelp C; Amann E
Anticancer Res; 1997; 17(4B):3051-3. PubMed ID: 9329599
[TBL] [Abstract][Full Text] [Related]
53. Serum placental-like alkaline phosphatase (PLAP): a novel combined enzyme linked immunoassay for monitoring ovarian cancer.
Fisken J; Leonard RC; Shaw G; Bowman A; Roulston JE
J Clin Pathol; 1989 Jan; 42(1):40-5. PubMed ID: 2921344
[TBL] [Abstract][Full Text] [Related]
54. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer.
Koelbl H; Schieder K; Neunteufel W; Bieglmayer C
Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933
[TBL] [Abstract][Full Text] [Related]
55. Immunological reactivity of mucinous and serous ovarian adenocarcinomas.
Harłozińska-Szmyrka A; Slesak B; Richter R; Rabczyński J; Cisło M
Cancer Detect Prev; 1986; 9(3-4):347-58. PubMed ID: 3017557
[TBL] [Abstract][Full Text] [Related]
56. Placental alkaline phosphatase (PLAP)/PLAP-like alkaline phosphatase as tumour marker in relation to CA 125 and TPA for ovarian epithelial tumours.
Stigbrand T; Riklund K; Tholander B; Hirano K; Lalos O; Stendahl U
Eur J Gynaecol Oncol; 1990; 11(5):351-60. PubMed ID: 2097151
[TBL] [Abstract][Full Text] [Related]
57. [Studies on the clinical significance of type III procollagen peptide in sera as a tumor marker in patients with ovarian tumors].
Mori T; Itoh E
Nihon Gan Chiryo Gakkai Shi; 1989 May; 24(5):974-89. PubMed ID: 2778385
[TBL] [Abstract][Full Text] [Related]
58. Monoclonal antibodies recognizing tumor-associated antigen of human ovarian mucinous cystadenocarcinomas.
Bhattacharya M; Chatterjee SK; Barlow JJ; Fuji H
Cancer Res; 1982 May; 42(5):1650-4. PubMed ID: 6175395
[TBL] [Abstract][Full Text] [Related]
59. Tumor associated antigen in ovarian carcinoma.
Negishi Y; Mutai Y; Akiya K; Fujiwara Y; Singh G
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jan; 36(1):126-32. PubMed ID: 6199439
[TBL] [Abstract][Full Text] [Related]
60. [Significance of CA 125 antigen levels in patients with ovarian cancer].
Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
